94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1522580
This article is part of the Research Topic The Tumor Microenvironment and Immunotherapy for Head and Neck Tumors View all 15 articles
The Key Role of DLX6 in Nasopharyngeal Carcinoma: Metastasis, Angiogenesis and Tumor Immune Mechanism
Provisionally accepted
Yang Hanxuan 1,2
Zeng Ximing 3
Xiaochuan Chen 1,2
Sunqin Cai 1,2 Li Yi Li 1,2 Xu Wenqian 1,2 Lai Jinghua 1
Sufang Qiu 1,2*- 1 Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China
- 2 Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province, China
- 3 Fuzhou Hospital of Traditional Chinese Medicine, Fuzhou, Fujian Province, China
Background: Precise management of gene expression is vital for the correct growth and operational efficiency of cells. Early-stage nasopharyngeal carcinoma (NPC) often presents asymptomatically, leading to delayed diagnosis, limited treatment options, and increased risk of recurrence and metastasis. This study investigates the role of DLX6 in NPC pathogenesis to enhance early screening and treatment.Immunohistochemistry and RNA sequencing were utilized to investigate the relationship between DLX6 expression in NPC tumor samples and clinical pathological factors. Clinical data from Fujian Cancer Hospital, along with sequencing analysis from the GEO databases, were used for bioinformatics analysis.NPC cell lines with DLX6 knockdown were established, and the impact of DLX6 on the biological traits of NPC cells was assessed through wound healing, transwell, colony formation, and EdU assays. The expression of EMT-related proteins and the PI3K-AKT pathways was examined using western blot analysis.Results: Immunohistochemistry validated the association between DLX6 and NPC prognosis, whereas RNA sequencing illustrated its expression levels in tissues and cells. Functional assays such as wound healing, transwell, and colony formation revealed that DLX6 knockdown adversely affected NPC cell proliferation, invasion, and migration. Bioinformatics analysis revealed that DLX6 is involved in pathways related to cell cycle, DNA replication, and cancer progression. Immune infiltration analysis showed that DLX6 expression affects the immune landscape in NPC, correlating positively with DC and TH17 cells, and negatively with cytotoxic T cells and B cells. Low DLX6 expression was associated with higher levels of chemokines and better immunotherapy outcomes.Our study indicates that DLX6 is a novel prognostic biomarker and potential therapeutic target for NPC, playing a critical role in metastasis, angiogenesis, and tumor immunity.
Keywords: distal-less homeobox 6, NPC, proliferation, Angiogenesis, tumor immunity
Received: 04 Nov 2024; Accepted: 12 Feb 2025.
Copyright: © 2025 Hanxuan, Ximing, Chen, Cai, Yi Li, Wenqian, Jinghua and Qiu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Sufang Qiu, Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.